Aquestive Therapeutics, Inc. AQST Non-cash interest expense
Non-cash interest expense at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s non-cash interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s non-cash interest expense?
- Aquestive Therapeutics, Inc. (AQST) reported non-cash interest expense of $2.29M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s non-cash interest expense changed year-over-year?
- Aquestive Therapeutics, Inc.'s non-cash interest expense decreased by 16.9% year-over-year, from $2.75M to $2.29M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s non-cash interest expense?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s non-cash interest expense has grown at a 31.0% compound annual growth rate (CAGR), from $3.73M to $11M.